Media

Stockhead – PharmAust’s monepantel drug could be a game-changer for MND/ALS patients, new data shows

Small Caps – PharmAust encouraged by positive monepantel survival rate assessment

Small Caps – PharmAust solidifies leadership team ahead of key Stage 2/3 MPL study

Stockhead – PharmAust puts experienced hands back on its rudder

Stockhead – ‘Outstanding milestone’: FDA grants PharmAust orphan drug designation for monepantel

Small Caps – PharmAust set to transform MND therapy landscape as monepantel receives FDA orphan drug designation

Stockhead – PharmAust plans for pivotal Phase 2/3 trial after key quarter of milestones

Small Caps – PharmAust gears for major clinical milestones in 2024, following strong start and FDA feedback

Small Caps – PharmAust appoints interim CEO as company plans for pivotal Phase 2/3 study

Stockhead – PharmAust bolsters manufacturing leadership to expand path to commercialisation

Small Caps – PharmAust appoints industry veteran to spearhead manufacturing ahead of critical MPL trial

Stockhead – PharmAust inks approval from Macquarie University for Open-Label MND extension study

Small Caps – PharmAust’s pioneering monepantel MND study receives HREC green light for final phase

The West – How PharmAust is offering hope to patients with MND and ALS using veterinary drug monepantel

Best Stocks – Revolutionizing ALS Treatment: New Findings Reveal Potential Game-Changer in Disease Management

Small Caps – Australian biotech sector tipped for strong growth

Stockhead – ‘Tide is turning for the healthcare sector’

Small Caps – PharmAust eyes FDA orphan drug designation for monepantel after positive MND/ALS trial results

Stockhead – PharmAust files groundbreaking MND/ALS clinical data with the FDA

ALS News Today – Vet drug monepantel slows ALS, MND disease progression in trial

Stockhead – ScoPo’s (actually Wilkie’s) Powerplays: Health stocks rise as AdAlta soars 17% on trial results

Small Caps Interview – PharmAust makes strong progress in monepantel study to treat MND/ALS

Money News Interview

BioWorld – Pivotal trial next for Pharmaust after MND/ALS phase I success

ausbiz Interview – “Exciting milestone” in the fight against motor neurone disease

Stockhead – PharmAust’s MPL could offer MND/ALS patients up to 56.5 months additional life expectancy

Small Caps – PharmAust’s monepantel study shows 58% slowdown in MND progression

Proactive – PharmAust advances monepantel for motor neurone disease towards FDA approval

Small Caps – PharmAust assembles world-class scientific advisory board to propel fight against neurodegenerative diseases

Stockhead – PharmAust forms scientific advisory board to guide next phase of monepantel for treatment of MND/ALS

ausbiz Interview

ALS News Today – FDA, PharmAust to meet over plans for Phase 2/3 trial of monepantel

Stockhead – PharmAust just got a pre-IND meeting with the US FDA to kick off ‘24

Stockhead – Santa (and ATO) delivers PharmAust $550k cash boost for Christmas

The Advertiser – (More) ASX biotechs with catalysts that could make them pop in 2024

Stockhead – Up to $1.8m funding from motor neurone disease foundation could be on the table for PharmAust

Stockhead – Prominent Perth fundie the main backer in PharmAust’s $3.5m cap raise

Small Caps – PharmAust adds highly-credentialled members to management team

Stockhead – Why this ASX biotech is primed to capitalise as big pharma flocks to the rare diseases market

The Australian – Results from 11 of 12 patients in PharmAust trial point to stabilised MND progression